Prospectus for Karo Bio's Rights Issue Available on Web Site
Not for distribution in the US, Australia, Japan, New Zealand or Canada. The Offer does not apply to persons whose participation requires further prospectuses, filings or other measures in excess of those implied by Swedish law. Prospectus for Karo Bio's rights issue available on web site Karo Bio has today announced the prospectus for the forthcoming new share issue with preferential rights for the Company's shareholders. The prospectus is available on Karo Bio's website at www.karobio.com/newissue and will also be distributed to the shareholders registered in the share register on the record date September 8, 2004. Terms in brief and time table Stated terms in brief and time schedule for the rights issue are listed below. · Each three shares held entitles to subscribe for two new shares · The subscription price is SEK 8.50 per share · Record date for participation in the rights issue is September 8, 2004 · Trading in subscription rights will take place September 13 - 28, 2004 · The subscription period is from September 13 - October 1, 2004 · Prospectus, subscription form and issue statement will be distributed to Karo Bio's shareholders beginning September 10, 2004 Huddinge, September 8 2004 KARO BIO AB For further information, please contact Bertil Jungmar, Chief Financial Officer, phone +46 8 608 60 52 Björn O. Nilsson, President & Chief Executive Officer, phone +46 8 608 60 20 Facts about Karo Bio Karo Bio has operations in Huddinge, Sweden, and 95 employees. Karo Bio has been listed on the Stockholm stock exchange (Reuters: KARO.ST) since 1998 and maintains a leading position in the field of drug discovery focused on nuclear receptors. Nuclear receptors are validated drug targets for a number of clinical indications and the Company uses proprietary technologies for the development of novel and improved therapies for major markets. Karo Bio has drug discovery programs in several therapeutic areas including women's health care, cancer, cardiovascular disease, atherosclerosis and diabetes. Karo Bio collaborates with major pharmaceutical companies for the development of products and marketing. In these collaborations Karo Bio receives upfront payments, R&D funding and milestone payments, as well as royalties on net sales when products reach the market. Karo Bio has strategic pharmaceutical drug discovery collaborations with Merck & Co., Inc. and Wyeth Pharmaceuticals. This press release is also available online at www.karobio.com and at www.waymaker.net. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/09/08/20040908BIT00020/wkr0001.pdf